|
Age (≤50/ >50 years)
|
69/164
|
56/71
|
0.006
|
|
Size (≤20/ 21-50/ >50 mm)
|
129/97/7
|
56/65/6
|
0.038
|
|
Grade (I / II / III)
|
156/73/13
|
56/53/21
|
<0.001
|
|
Involved lymph node (0/1-3/ >3)
|
153/80
|
53/74
|
<0.001
|
|
ER status (no/yes)
|
102/131
|
69/58
|
0.056
|
|
PR status (no/yes)
|
118/115
|
76/51
|
0.095
|
|
HER2 status (no/yes)
|
193/40
|
96/31
|
0.099
|
|
Endocrine therapy (no/yes)
|
168/62
|
104/19
|
0.014
|
|
Chemotherapy (no/yes)
|
150/80
|
59/64
|
0.002
|
|
Tumour recurrence (no/local/distant/both)
|
199/5/28/1
|
72/12/39/4
|
<0.001
|
|
Alive/cancer death/non cancer death
|
141/39/53
|
48/58/21
|
0.059
|
|
Cancer specific survival (months)a
|
186(177–194)
|
134(120–149)
|
<0.001
|
|
Node-negative disease (n = 206)
|
n = 153 (74%)
|
n = 53 (26%)
| |
|
Age (≤50/ >50 years)
|
42/111
|
25/28
|
0.008
|
|
Size (≤20/ 21-50/ >50 mm)
|
96/55/2
|
24/27/2
|
0.019
|
|
Grade (I / II / III)
|
33/53/67
|
1/20/32
|
0.002
|
|
ER status (no/yes)
|
32/48
|
40/34
|
0.082
|
|
PR status (no/yes)
|
38/42
|
43/31
|
0.189
|
|
HER2 status (no/yes)
|
130/23
|
38/15
|
0.032
|
|
Endocrine therapy (no/yes)
|
106/46
|
43/9
|
0.070
|
|
Chemotherapy (no/yes)
|
111/41
|
31/21
|
0.070
|
|
Tumour recurrence (no/local/distant/both)
|
137/4/11/1
|
33/4/14/2
|
<0.001
|
|
Alive/cancer death/non cancer death
|
99/18/36
|
25/17/11
|
0.266
|
|
Cancer specific survival (months)a
|
198(190–206)
|
153(131–174)
|
0.001
|
|
Triple-negative patients (n = 120)
|
n = 74(62%)
|
46(38%)
| |
|
Age (≤50/ >50 years)
|
26/48
|
24/22
|
0.064
|
|
Size (≤20/ 21-50/ >50 mm)
|
42/28/4
|
21/23/2
|
0.367
|
|
Grade (I / II / III)
|
1/13/60
|
0/8/38
|
0.712
|
|
Involved lymph node (-ve/+ve)
|
52/22
|
18/28
|
0.001
|
|
Endocrine therapy (no/yes)
|
65/9
|
42/3
|
0.336
|
|
Chemotherapy (no/yes)
|
36/38
|
15/30
|
0.103
|
|
Tumour recurrence (no/local/distant)
|
64/0/10
|
24/3/19
|
<0.001
|
|
Alive/cancer death/non cancer death
|
48/13/13
|
18/24/4
|
0.217
|
|
Cancer specific survival (months)a
|
176(161–192)
|
122(96–147)
|
<0.001
|
